Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the car...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Heart Fail
Main Authors: Teerlink, John R., Voors, Adriaan A., Ponikowski, Piotr, Pang, Peter S., Greenberg, Barry H., Filippatos, Gerasimos, Felker, G. Michael, Davison, Beth A., Cotter, Gad, Gimpelewicz, Claudio, Boer‐Martins, Leandro, Wernsing, Margaret, Hua, Tsushung A., Severin, Thomas, Metra, Marco
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2017
Teme:
Trial Design
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488179/
https://ncbi.nlm.nih.gov/pubmed/28452195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.830
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki